ANTI-GTN

Uses

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project (www.proteinatlas.org)and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. To view these protocols and other useful information about Prestige Antibodies and the HPA, visit .

General Description

Catenin delta 1 (CTNND1), the 120 kDa catenin-related protein is also referred as catenin p120ctn, p120cas and pp120 src substrate. p120ctn contains a central armadillo repeat domain (ARM domain) and is structurally similar to β-catenin and γ-catenin. It codes for a member of the Armadillo (Arm) family of proteins. This gene is located on human chromosome 11q12.

Biochem/physiol Actions

Catenin delta 1 (CTNND1/p120ctn) is described as a prominent substrate for the Src oncoprotein and a variety of receptor tyrosine kinases (RTKs) including those for epidermal growth factor (EGF), platelet derived growth factor (PDGF) and colony stimulating factor-1 (CSF-1). It can bind directly to the cytoplasmic domain of the epithelial E-cadherin via the armadillo repeat domain (ARM) domain. It co-precipitates in multiprotein complexes containing E-cadherin or other cadherins such as neural (N)- or placental (P)- cadherins, depending on the cell type. CTNND1 participates in the oncogenesis of some cancer. It can serve as a tumor oncogene in hepatocellular carcinoma (HCC).